| Similar Articles |
|---|
 |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support.   |
Pharmaceutical Executive
October 1, 2005 |
Changing Diabetes An interview with Novo Nordisk's president of U.S. operations Martin Soeters on how a nation that leads the world in diabetes research does such a poor job of treating it. Here, he offers some solutions. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
IEEE Spectrum
January 2011
Sandra Upson |
Bionic Pancreas Artificial organ could improve control over diabetes |
Managed Care
October 2005
Thomas Morrow |
Incretin Hormones Poised For Better Control of Diabetes Enhanced management continues due to a greater understanding of the intricate glucose balance and the shortfalls of existing medications. |
Pharmaceutical Executive
August 1, 2008
Gayle Lorenzi et al. |
Spanning the Treatment Gap How a diabetes field team helped docs overcome the treatment gap. |
The Motley Fool
May 10, 2011
Brian Orelli |
Uncontrolled Crying Over AVANIR's Prescription Data? It's been a slow start, but don't write off this company's pseudobulbar drug just yet. |
Chemistry World
September 24, 2010
Andrew Turley |
End of the road for Avandia? The European Medicines Agency has decided the troubled diabetes drug should be pulled from the market while the US Food and Drug Administration has said it will 'significantly restrict' its use. |
American Family Physician
March 15, 2001
Goutham Rao |
Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value... |
The Motley Fool
January 7, 2011
Brian Orelli |
A Biotech Roller Coaster Lexicon is back on the upswing. |
HHMI Bulletin
Fall 2012
Sarah C. P. Williams |
The Fat You Can't See Without the liver acting as a filter and energy producer, a person can't survive, and no artificial organ can perform all of its duties. But in one in three Americans -- and similar numbers in other developed nations -- the liver has lost its luster. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
The Motley Fool
June 9, 2011
Brian Orelli |
XOMA Breaks Bad News to Investors XOMA 052 continues to be a disaster in diabetes. |
Nurse Practitioner
May 2011
Stacey A. Seggelke |
Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes. |
Chemistry World
July 30, 2007
James Mitchell Crow |
Cell Transplant Hope for Diabetes Sufferers Iron-based 'magnetocapsules' of insulin-producing cells could help doctors use cell transplants to treat type I diabetes. |
Nursing
September 2010
Margaret M. Bolton |
Sounding the alarm about metabolic syndrome Any health problem that affects a third of American adults is sure to impact your nursing practice. Metabolic syndrome, a growing and commonly silent condition, poses a significant public health crisis. |
Pharmaceutical Executive
January 1, 2012
Elys Roberts & Sarah Phillips |
The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all? |
Chemistry World
August 23, 2013
Jessica Cocker |
Plant protein regulates diabetes treatment A plant protein has been used to make a new class of glucose-responsive polymer nanogels that could one day negate the need for diabetes patients to constantly monitor their blood glucose levels and inject themselves with insulin. |
Nursing
November 2009
Christine Kessler |
Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia. |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
Managed Care
December 2003
Thomas Morrow |
Can Amylin Analogue Lead To Better Diabetes Control? Maintaining tight glucose control is difficult to accomplish, but adding amylin to the mix may be the answer. |
The Motley Fool
September 28, 2010
Brian Orelli |
Don't Get Stuck! Invest in Needle-Free Drugs Here's how to make some money off society's general disdain for needles through next-generation drugs. |
Search Engine Watch
February 20, 2011
Dean Stephens |
Social Networks and Health: Bad Medicine? Social networks can be invaluable for helping consumers with health care decisions, as well as brand awareness for health practitioners, organizations, and treatments -- as long as it's done right. |
Scientific American
December 12, 2005
Philip E. Ross |
Grow Your Own Getting a diabetic pancreas to regrow its islets -- growth factors could restore beta cells lost in type 1 diabetes. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
Pharmaceutical Executive
March 1, 2013
Ben Comer |
Brand of the Year: Januvia When Merck's Januvia received its first regulatory approval, in Mexico in 2006, no one predicted its long-term success. In 2012, the company's diabetes franchise became the highest-selling product family in Merck's 122-year history. |
Fast Company
April 2012
Tara Moore |
Diane Curley Is Starting The Conversation To Curb Obesity This year, the U.S. government started a program for health-care innovators. One innovator, Diane Curly is treating obesity like any other disease or addiction and trains nurses to talk to patients about treatment. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
Pharmaceutical Executive
September 1, 2012
Al Topin |
Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
Pharmaceutical Executive
June 1, 2009
Michael Maher |
Learning to Relate A multi-phase implementation strategy can debunk the myth that social media won't work for pharma. |
The Motley Fool
June 29, 2010
Brian Orelli |
Diabetes Drug Development Pops and Drops When companies present at a major meeting, there's bound to be both. |
Pharmaceutical Executive
November 1, 2014
William Looney |
Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
October 1, 2011 |
Arming up for the Digital Revolution As a longtime advocate of new approaches to meeting customer needs in pharma, Martin Wygod sees the biggest change as the coming growth of digital platforms as the principal source of information and communication in healthcare. |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive
May 1, 2009 |
The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded? |
Pharmaceutical Executive
December 1, 2006 |
Thoughtleader: Thomas Ebeling, Novartis The Next Big Thing: An interview with the pharma's CEO, who has witnessed tremendous financial and scientific growth at the company and is on the brink of his next major milestone. |
The Motley Fool
October 2, 2009
Brian Orelli |
Warning! Potential Blockbuster Ahead It's a little early to call it, but it looks like Bristol-Myers Squibb and AstraZeneca have a potential blockbuster on their hands with their new diabetes drug. |
Pharmaceutical Executive
December 1, 2013
Vansgaard et al. |
Develop Drugs for People, Not Just Bodies A patient-centric approach to drug development delivers the benefits that actually create value |
The Motley Fool
November 24, 2010
Brian Orelli |
Profit From the United States of Diabetes Half the country could have an early form by 2020. |
Chemistry World
March 15, 2011
Sarah Houlton |
Benlysta breaks 50 year Lupus drug drought The first new treatment for lupus erythematosus in half a century has been approved by the US Food and Drug Administration |
Pharmaceutical Executive
October 1, 2010 |
When the Payer IS the Player As Medicare, Medicaid, and the nation's web of private payers gain market power, how can pharma stay ahead of the cost-containment curve? |
The Motley Fool
August 10, 2010
Ryan McBride |
Vertex's Telaprevir Clears Hurdle, Could Halve Treatment Times for Hepatitis C Study results are positive. |
The Motley Fool
December 3, 2010
Brian Orelli |
Merck Smartens Up The acquisition of SmartCells looks like an intelligent move. |
Pharmaceutical Executive
September 1, 2012
Ben Comer |
You Tell Me Specialized knowledge about disease and treatment is no longer the exclusive province of practicing physicians. For biopharmaceutical manufacturers, patient feedback can help to elucidate an unmet need. |
Managed Care
July 2004
Udaya M. Kabadi |
Cost-Effective Management of Hyperglycemia in Patients with Type 2 Diabetes Using Oral Agents Sulfonylureas are cost-effective and also may be the only oral agents that inhibit processes inducing hyperglycemia by improving insulin secretion and insulin resistance. New long-acting agents hold even greater promise. |
